Search

everythinglearnresearchcommunity

for

Search:↓

A 22-year-old shared his 15-month progress using finasteride and 12-month progress with minoxidil for hair loss, noting improved thickness but minimal hairline change. He experienced initial shedding with minoxidil but no side effects from finasteride, and he advises patience and consistency for results.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

Fucoidan may help regrow hair and reduce inflammation in androgenetic alopecia. It is unclear if simply mixing fucoidan powder into a serum for application is effective.

The user used microneedling, zinc, vitamin D3, biotin, magnesium, saw palmetto, pumpkin seed oil, and a DHT-blocker shampoo with biotin for hair loss. They are considering adding minoxidil due to stagnation in progress.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

The user shared their hair regrowth progress using a regimen including omega-3, flaxseed, EGCG, green tea, zinc, copper, probiotics, microneedling, topical finasteride, and minoxidil. Other users expressed skepticism about the effectiveness of the regimen, suggesting more proven treatments or considering a hair transplant.

People are excited about a new hair loss treatment, PP405, and some suggest using Twitter to increase its visibility. Current treatments mentioned include finasteride, minoxidil, and dutasteride, but skepticism remains about the effectiveness of new treatments.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.